AstraZeneca’s planned vaccine hub for Liverpool is off the table - business editor Karl Matchett and Whitehall editor Kate ...
Q4 2024 Earnings Call Transcript February 6, 2025 AstraZeneca PLC misses on earnings expectations. Reported EPS is $1.05 EPS, ...
17hon MSN
Cancer researchers are one step closer to developing an effective vaccine to treat people with clear cell renal cell ...
Ken Hall takes a look at two big-name retirement shares in the FTSE 100 with market-leading positions and track records of solid dividend payouts.
It isn’t just artificial intelligence. Chinese biotech companies are now developing drugs faster and cheaper than their US ...
Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...
Though highly effective, medications for the prevention of chronic kidney disease progression are under-utilized, emphasizing the need for better use of prognostic tools.
Investing.com -- AIM ImmunoTech (NYSE: AIM) Inc. (NYSE American: AIM) has announced its intention to develop Ampligen as a vaccine adjuvant for avian influenza. This move is part of AIM's antiviral ...
12h
HealthDay on MSNStudy Finds Exenatide Not Beneficial for Parkinson DiseaseThe glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson disease seve ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results